Devote Biotech Today,Create Health Tomorrow
Devote Biotech Today,Create Health Tomorrow

Devote Biotech Today,Create Health Tomorrow

视频标题

ABOUT BCHT ABOUT BCHT ABOUT BCHT ABOUT BCHT ABOUT BCHT ABOUT BCHT

Devote Biotech Today,Create Health Tomorrow

ABOUT US


Changchun BCHT Biotechnology Co.

Changchun BCHT Biotechnology Co. (hereinafter referred to as “BCG Biotech” or the “Company”) is an innovative biopharmaceutical enterprise primarily dedicated to the prevention and control of infectious diseases. Since its establishment in 2004, the Company has been engaged mainly in the research and development, production, and sales of human vaccines. Through years of growth, it has gradually built a comprehensive operational system centered around its core products and implemented full-lifecycle quality management for its products—including raw material procurement, project R&D, production management, product distribution, quality control, and quality assurance—all of which are supported by stringent management measures and internal control systems at every stage.

Learn More
Company establishment date
2004 Year

Company establishment date

Total land area
225700 square meters

Total land area

Existing employees
1000 +

Existing employees

Medicines benefit countries and regions.
10 +

Medicines benefit countries and regions.

Innovative R&D

Dedicated to biotechnology, creating a healthy future.


R&D Team

Learn More

Listed products

Dedicated to biotechnology, creating a healthy future.

Shingles Live Attenuated Vaccine, Ganwei®

According to CDC data, 30% of individuals will develop shingles at some point in their lives. As age increases, the prevalence of VZV IgG antibody positivity rises steadily, with rates exceeding 98% among those aged 40 and older, indicating that the risk of shingles increases with advancing age.

Learn more >

Live attenuated varicella vaccine

The live attenuated varicella vaccine developed by Baike Biotech utilizes the WHO-recommended MRC-5 human diploid cell line as the production cell substrate and the WHO-recommended Oka strain of varicella virus as the production viral strain. Moreover, it incorporates the company’s proprietary BH-2 lyophilization protectant, which effectively addresses the challenge of maintaining high-titer stability in the varicella vaccine.

Learn more >

Lyophilized Live Attenuated Influenza Vaccine for Nasal Spray, Ganwu®

The lyophilized live attenuated influenza nasal spray vaccine (Ganwu®) is a Global Action Plan on Influenza (GAP) project implemented in collaboration with the World Health Organization (WHO). To date, hundreds of millions of doses have been administered worldwide, and Changchun Baike Biotechnology Co., Ltd. holds the exclusive manufacturing and marketing rights for this product within China.

Learn more >

Nasal Spray Live Attenuated Influenza Vaccine, Ganwu®

Following vaccination with this product, the body is stimulated to produce immunity against influenza viruses, thereby preventing influenza caused by influenza virus strains covered by the vaccine.

Learn more >

News Updates

Follow us to stay up-to-date with the latest news.

Learn More

Contact Us

Dedicated to biotechnology, creating a healthy future.

Address

No. 1260 Huoju Road, High-Tech Industrial Development Zone, Changchun City